Related Experiment Video
Updated: Jul 10, 2026
09:28
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
10.1K
Implementation of pharmacogenomics: Experience at Ochsner Health
Catherine B Oliver1, Dhara Naik2, Mark Kirkikis2
1Clinical Pharmacy Services, Ochsner Health, New Orleans, LA, USA.
Summary
Pharmacogenomics, the study of genetic influences on drug response, offers pharmacists a key role in precision medicine. Implementing a clinical pharmacogenomics service involves strategic planning for testing, patient selection, reimbursement, and workforce education.
Area of Science:
- Pharmacogenomics
- Precision Medicine
- Clinical Pharmacy
Background:
- Pharmacogenomics investigates genetic variations affecting individual drug responses.
- Pharmacists, as medication experts, are well-positioned to lead pharmacogenomics practice.
- Precision medicine leverages individual variability for optimized therapeutic strategies.
Purpose of the Study:
- To describe fundamental operational aspects of developing a clinical pharmacogenomics practice.
- To discuss the experience of a multisite health system in establishing a pharmacogenomics service.
- To highlight the role of pharmacists in advancing pharmacogenomics.
Main Methods:
- Review of operational aspects for pharmacogenomics practice development.
- Case study of a multisite health system's pharmacogenomics service implementation.
- Analysis of key considerations including testing, patient targeting, reimbursement, and education.
Main Results:
- Pharmacogenomics services can be preemptive or reactive, in-house or outsourced, and panel-based or single-gene.
- Successful deployment requires targeting specific patient populations across various medical specialties.
- Reimbursement models for pharmacogenomics are variable and present implementation challenges.
Conclusions:
- Key considerations for developing a pharmacy-driven pharmacogenomics service include testing strategy, patient population, reimbursement, practice design, and workforce education.
- Growing demand exists for pharmacogenomics education for pharmacy students and professionals.
- Clinical pharmacy-led pharmacogenomics services present a significant opportunity to enhance patient care outcomes and experiences.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...